Specifically targeted gene therapy for small-cell lung cancer.
Small-cell lung cancer (SCLC) is a highly malignant disease with poor prognosis. Hence, there is great demand for new therapies that can replace or supplement the current available treatment regimes. Gene therapy constitutes a promising strategy and relies on the principle of introducing exogenous DNA into malignant cells causing them to die. Since SCLC is a highly disseminated malignancy, the gene therapeutic agent must be administered systemically, obligating a high level of targeting of tumor tissue and the use of delivery vehicles designed for systemic circulation of the therapeutic DNA. This review describes and discusses the current status of the application of gene therapy in relation to SCLC.
Christensen
Camilla L
CL
Department of Radiation Biology, The Finsen Center, section 6321, Copenhagen University Hospital, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark.
Zandi
Roza
R
Gjetting
Torben
T
Cramer
Frederik
F
Poulsen
Hans S
HS
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D004274:DNA, Recombinant / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015195:Drug Design; D005813:Genes, Synthetic; D041722:Genes, Transgenic, Suicide; D016147:Genes, Tumor Suppressor; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D051379:Mice; D011401:Promoter Regions, Genetic; D014158:Transcription, Genetic; D023041:Xenograft Model Antitumor Assays
D004274:DNA, Recombinant; D008081:Liposomes